Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Amstutz, Ursula ^a   Farese, Simone ^a   Aebi, Stefan ^a   Largiadèr, Carlo R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; PLATINUM DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DERMATOLOGIC TOXICITY; EPIGENETICS; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE SEQUENCE; HEMATOLOGIC TOXICITY; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MOLECULAR CLONING; MONOTHERAPY; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RECTUM CANCER; STOMACH CANCER; TONSIL CANCER; DNA METHYLATION; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; NEOPLASM; POLYMERASE CHAIN REACTION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DNA METHYLATION; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 56349087342     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-54     Document Type: Article

References (24)

1. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. H Ezzeldin R Diasio, Clin Colorectal Cancer 2004 4 181 189 10.3816/CCC.2004.n.018 15377401
2. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. E Levy P Piedbois M Buyse JP Pignon P Rougier L Ryan R Hansen B Zee B Weinerman J Pater, J Clin Oncol 1998 16 3537 3541 9817272
3. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? G Milano HL McLeod, Eur J Cancer 2000 36 37 42 10.1016/S0959-8049(99) 00211-7 10741292
4. Population study of dihydropyrimidine dehydrogenase in cancer patients. M Etienne J Lagrange O Dassonville R Fleming A Thyss N Renée M Schneider F Demard G Milano, J Clin Oncol 1994 12 2248 2253 7964939
5. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. A Van Kuilenburg, Eur J Cancer 2004 40 939 950 10.1016/j.ejca.2003.12.004 15093568
6. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. L Mattison R Soong R Diasio, Pharmacogenomics 2002 3 485 492 10.1517/14622416.3.4.485 12164772
7. Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. A Lazar UA Mau-Holzmann H Kolb HE Reichenmiller O Riess E Schömig, Onkologie 2004 27 559 562 10.1159/000081338 15591715
8. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. M Raida W Schwabe P Häusler A Van Kuilenburg A Van Gennip D Behnke K Höffken, Clin Cancer Res 2001 7 2832 2839 11555601
9. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. K Seck S Riemer R Kates T Ullrich V Lutz N Harbeck M Schmitt M Kiechle R Diasio E Gross, Clin Cancer Res 2005 11 5886 5892 10.1158/1078-0432.CCR-04-1784 16115930
10. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. X Wei HL McLeod J McMurrough FJ Gonzalez P Fernandez-Salguero, J Clin Invest 1996 98 610 615 8698850 10.1172/JCI118830
11. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. P Vreken AB Van Kuilenburg R Meinsma GP Smit HD Bakker RA De Abreu AH van Gennip, J Inherit Metab Dis 1996 19 645 654 10.1007/BF01799841 8892022
12. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. H Ezzeldin A Lee L Mattison R Diasio, Clin Cancer Res 2005 11 8699 8705 10.1158/1078-0432.CCR-05- 1520 16361556
13. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. U Amstutz S Farese S Aebi CR Largiadèr
14. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. S Shestopal M Johnson R Diasio, Biochim Biophys Acta 2000 1494 162 169 11072080
15. Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group. M Schwab UM Zanger C Marx E Schaeffeler K Klein J Dippon R Kerb J Blievernicht J Fischer U Hofmann, J Clin Oncol 2008 26 2131 2138 10.1200/JCO.2006.10.4182 18299612
16. Common Terminology Criteria for Adverse Events v3.0. http://ctep.cancer. gov/reporting/ctc_v30.html
17. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. N Magné MC Etienne-Grimaldi L Cals N Renée JL Formento M Francoual G Milano, Br J Clin Pharmacol 2007 64 237 240 17335544 10.1111/j.1365-2125.2007.02869.x
18. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. A Morel M Boisdron-Celle L Fey P Soulie MC Craipeau S Traore E Gamelin, Mol Cancer Ther 2006 5 2895 2904 10.1158/1535-7163.MCT-06-0327 17121937
19. Predicting fluorouracil toxicity: can we finally do it? HH Ezzeldin RB Diasio, J Clin Oncol 2008 26 2080 2082 10.1200/JCO.2007.15.5481 18299611
20. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. ESR Collie-Duguid MC Etienne G Milano HL McLeod, Pharmacogenetics 2000 10 217 223 10.1097/00008571-200004000-00002 10803677
21. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. W Ichikawa T Takahashi K Suto Y Sasaki R Hirayama, Clin Cancer Res 2006 12 3928 3934 10.1158/1078-0432. CCR-05-2665 16818689
22. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. T Lecomte J Ferraz F Zinzindohoué M Loriot D Tregouet B Landi A Berger P Cugnenc R Jian P Beaune P Laurent-Puig, Clin Cancer Res 2004 10 5880 5888 10.1158/1078-0432.CCR- 04-0169 15355920
23. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. M Etienne K Ilc J Formento P Laurent-Puig P Formento S Cheradame J Fischel G Milano, Br J Cancer 2004 90 526 534 10.1038/sj.bjc.6601523 14735204
24. Cancer pharmacogenetics: polymorphisms, pathways and beyond. C Ulrich K Robien H McLeod, Nat Rev Cancer 2003 3 912 920 10.1038/nrc1233 14740638